FDA approves earlier use of Carvykti CAR-T for multiple myeloma 

FDA approves earlier use of Carvykti CAR-T for multiple myeloma  - Blog

The FDA has approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma. Ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech), also known as cilta-cel, is a B-cell maturation antigen (BCMA)-directed CAR T cell therapy previously approved for use in adults with relapsed or refractory multiple myeloma after four lines of treatment. […]

 Cancer Cells Deliver CRISPR to Fight Cancer

 Cancer Cells Deliver CRISPR to Fight Cancer - Blog

In a study, researchers have developed a novel CRISPR-Cas9 delivery system using cryo-choked lung tumor cells to target Non-Small Cell Lung Cancer (NSCLC), particularly those with KRAS mutations. The technique involves using lung tumor cells treated by rapid shock with liquid nitrogen, effectively inactivating their pathogenicity while preserving their structure and surface receptors. These cryo-choked […]

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma - Blog

CARv3-TEAM-E T cells are CAR T cells targeting EGFR variant III tumor-specific antigen (EGFRvIII) in addition to wild-type EGFR. According to the results of the phase 1 INCIPIENT trial (NCT05660369) published in the New England Journal of Medicine, preliminary results in humans demonstrated that all 3 glioblastoma patients treated with CARv3-TEAM-E T cells between March […]

Novel dual-target CAR T cell therapy shows promise in treating recurrent glioblastoma

Novel dual-target CAR T cell therapy shows promise in treating recurrent glioblastoma - Blog

Glioblastoma (GBM) is the most common and aggressive type of cancerous brain tumor in adults. People with GBM generally expect to live 12 to 18 months after diagnosis. Despite decades of research, there is no known cure for GBM, and treatments have only a limited effect on extending an individual’s life expectancy. However, researchers have […]

Breakthrough immunotherapy targets non-cancer cells to prevent breast cancer spread

Breakthrough immunotherapy targets non-cancer cells to prevent breast cancer spread - Blog

Researchers have carried out a study of CAR-T cells in breast cancer. However, this therapy doesn’t always work on tumors, as their environment suppresses the immune response, and it can also be difficult to find specific features of breast cancer cells to target. To circumvent these challenges, the team directed CAR-T cells at cells surrounding […]

Natural killer cells lead the charge in cancer treatment innovation

Natural killer cells lead the charge in cancer treatment innovation - Blog

In a recent study published in the journal Nature, researchers have compiled the available literature on natural killer (NK) cells, innate immune cells involved in the recognition and elimination of cells in distress, particularly virus-infected cells and tumors. They focus on reviewing current preclinical and clinical research in the field of NK therapies, primarily elucidating […]

New DNA recombination toolbox surpasses CRISPR for genome engineering

New DNA recombination toolbox surpasses CRISPR for genome engineering - Blog

Belgian researchers from the VIB-KU Leuven Center for Microbiology and the VIB-UGent Center for Plant Systems Biology have extended the toolbox that uses a viral recombinase (Cre) so that it can now specifically recognize, cut and paste multiple DNA sites. The team has identified a set of 16 sites that recombine efficiently with the same […]

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

Penn analysis shows low risk of secondary cancers following CAR T cell therapy - Blog

Researchers at the University of Pennsylvania’s Perelman School of Medicine have conducted a study, published in Nature Medicine, which shows that the development of any type of second cancer after CAR T cell therapy is a rare phenomenon. Of 449 patients treated with commercially available CAR T cell therapies at Penn Medicine between January 2018 […]